SimBioSys, a Chicago IL-based AI and Biophysical company providing the TumorScope software platform, raised $15M in Series A funding.
The round was led by Genoa Ventures and Northpond Ventures with participation from AV8 Ventures, Heritage Medical Group, and Mayo Clinic. Andrea Jackson at Northpond Ventures and Vikram Chaudhery at Genoa Ventures will join the SimBioSys Board of Directors.
The company intends to use the funds to accelerate the development and commercialization of its TumorScope software platform.
Led by Tushar Pandey, CEO, SimBioSys provides a novel, simulation-based, precision medicine platform that enables individualized treatment planning for cancer patients. The company’s technology virtualizes individual tumors and – through biophysical simulations – delivers insights on specific traits, such as tumor morphology, drug delivery and metabolism, while simultaneously predicting response to therapy.
SimBioSys’ application combines artificial intelligence with biophysical simulations to model the impact of phenomena such as drug delivery, metabolism, and spatial heterogeneity in a comprehensive model using standard-of-care data alone. The results are generated within minutes, enabling physicians to make informed decisions while improving patient experience and shared decision-making. In addition, the technology can support the drug development process across pre-clinical and clinical trial settings.
In the first half of 2021, SimBioSys tripled its headcount, bringing in expert clinicians, scientists, and executives from the life sciences industry. The company is also working in collaboration with 20 leading cancer institutions across the country to run clinical validation studies. It recently published results from independent validation performed by prestigious cancer centers, demonstrating over 90 percent accuracy in predicting response to therapy in its first indication of early breast cancer.